Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 2, 2026
- Krystal Biotech reported $127.3 million in third-quarter VYJUVEK revenue and $63.1 million in net income, ended September 30, 2026 with $1.2 billion in cash and investments, and authorized a share repurchase program of up to $400 million.
- 10-Q report · filed Nov 2, 2026
- Krystal Biotech reported VYJUVEK product revenue, net of $127.3 million for the three months ended September 30, 2026, versus $97.8 million, with a 94% gross margin. Nine-month product revenue, net was $362.9 million, and cumulative revenue since 2023 reached $1,093.3 million.
The audio replay and transcript follow the call.